drugset
drugset / Trial / NCT05877651

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

NCT05877651 ↗

Phase 1 Completed 22 enrolled HRYZ Biotech Co.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients with metastatic or recurrent solid tumors who failed standard therapy.

Timeline

Start
2020-04-21
Primary completion
2021-10-15
Completion
2021-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject MASCT-I injection Cell therapy — —

Indications

cancer